Stockscreener 앱 받기
13.28
4.80%
-0.67
전일 마감가:
$13.95
열려 있는:
$13.91
하루 거래량:
615.69K
Relative Volume:
2.21
시가총액:
$1.72B
수익:
$65.48M
순이익/손실:
$-94.46M
주가수익비율:
-18.01
EPS:
-0.7375
순현금흐름:
$-71.18M
1주 성능:
-7.07%
1개월 성능:
-7.84%
6개월 성능:
-17.46%
1년 성능:
-26.59%
1일 변동 폭
$12.94
$13.91
1주일 범위
$12.94
$14.47
52주 변동 폭
$12.94
$21.50
Mesoblast Ltd Adr Stock (MESO) Company Profile
Compare MESO vs VRTX, MRNA, REGN, ARGX, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MESO
Mesoblast Ltd Adr
|
13.28 | 1.72B | 65.48M | -94.46M | -71.18M | -0.7375 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Mesoblast Ltd Adr Stock (MESO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-25 | 업그레이드 | Jefferies | Hold → Buy |
| 2025-07-18 | 다운그레이드 | Jefferies | Buy → Hold |
| 2024-12-23 | 다운그레이드 | Jefferies | Buy → Hold |
| 2024-09-24 | 업그레이드 | Maxim Group | Hold → Buy |
| 2024-08-29 | 업그레이드 | Jefferies | Hold → Buy |
| 2024-07-23 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2023-08-31 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-08-07 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2023-08-04 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2023-08-04 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2023-03-09 | 개시 | William Blair | Outperform |
| 2022-12-06 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-09-06 | 개시 | Piper Sandler | Overweight |
| 2021-04-07 | 업그레이드 | Maxim Group | Hold → Buy |
| 2020-12-22 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2020-12-04 | 다운그레이드 | Chardan Capital Markets | Neutral → Sell |
| 2020-10-22 | 개시 | RBC Capital Mkts | Sector Perform |
| 2020-08-14 | 재확인 | Maxim Group | Buy |
| 2020-05-28 | 재확인 | H.C. Wainwright | Buy |
| 2019-01-31 | 재개 | H.C. Wainwright | Buy |
| 2018-03-22 | 다운그레이드 | Credit Suisse | Neutral → Underperform |
| 2018-02-28 | 재확인 | Cantor Fitzgerald | Buy |
| 2017-08-31 | 개시 | Oppenheimer | Outperform |
| 2017-06-08 | 개시 | Cantor Fitzgerald | Buy |
모두보기
Mesoblast Ltd Adr 주식(MESO)의 최신 뉴스
Mesoblast (MESO) Slips 1.68% to $14.08 as Shares Pull Back From Recent HighsSocial Sentiment - siam.in
Mesoblast (MESO) Slips 1.68% to $14.08 as Shares Pull Back From Recent HighsNAAIM Exposure - dars.gov.et
Mesoblast (NASDAQ: MESO) Secures FDA Approval for TIBA Potency Assay in Ryoncil Production - Kalkine Media
MEOBF Form 4 FilingsMESOBLAST LTD SEC Form 4 - Stock Titan
Stevanato Group S.p.A. (STVN) Stock Price & News - Syfe
Mesoblast LimitedADR Key Financial Ratios – Valuation, Profitability & More - Value Research
Mesoblast LimitedADR Peer Comparison – Compare with Others - Value Research
Jupiter Neurosciences, Inc. Warrants (JUNSW) Peer Comparison – Compare with Others - Value Research
Arena Pharmaceuticals Inc (ARNA) Peer Comparison – Compare with Others - Value Research
Mesoblast Limited Files Annual Form 20-F with US SEC for Fiscal Year Ended June 30, 2026 - Kalkine
Earnings call transcript: Mesoblast posts $115 million in FY2026 revenue, stock slips - Investing.com
Mesoblast (NASDAQ: MESO) gives director 875,000 incentive options - stocktitan.net
Mesoblast (MESO) Latest: Falls 2.47% to $17.00 in the Current Update; Price Levels: Support at $16.15 and Resistance at $17.85 Frame the Range for the Current SessionAnchored VWAP - careplusvn.com
Mesoblast (MESO) Latest: Falls 2.47% to $17.00 in the Current Update; Price Levels: Support at $16.15 and Resistance at $17.85 Frame the Range for the Current SessionPullback Trade - dars.gov.et
Mesoblast (MESO) Latest: Falls 2.47% to $17.00 in the Current Update; Price Levels: Support at $16.15 and Resistance at $17.85 Frame the Range for the Current SessionDonchian Channel - www.dars.gov.et
Mesoblast (MESO) Momentum: Ends Up by 1.56% at $16.93; Next Session: Price Remains Between $16.08 Support and $17.78 ResistanceLinear Regression - careplusvn.com
Mesoblast (MESO) Momentum: Ends Up by 1.56% at $16.93; Next Session: Price Remains Between $16.08 Support and $17.78 ResistanceZero Lag EMA - dars.gov.et
Mesoblast (MESO) Momentum: Ends Up by 1.56% at $16.93; Next Session: Price Remains Between $16.08 Support and $17.78 ResistanceCup and Handle - www.dars.gov.et
Mesoblast Targets $10 Billion Market With Regenerative Back Pain Treatment - Sahm
H World Group Posts Upbeat Q2 Results, Joins Almonty Industries, Diana Shipping And Other Big Stocks Movi - Benzinga
Mesoblast Shares Jump 8.82% on ASX as Biotech Rebounds From Friday's Sharp Selloff Tied to State Street Filing - International Business Times Australia
ETFs Investing in Mesoblast Limited Sponsored ADR Stocks - tradingview.com
MESO Q1 2026 Earnings: EPS Slightly Misses Estimates on Pre-Revenue Loss, Shares Rise 2.97% - careplusvn.com
MESO Q1 2026 Earnings: EPS Slightly Misses Estimates on Pre-Revenue Loss, Shares Rise 2.97%Positive Surprise Momentum - www.dars.gov.et
Why Mesoblast (NASDAQ:MESO) Sees NASDAQ Composite Spotlight Now? - Kalkine Media
MESO Q1 2026 Earnings: EPS Misses Estimates, Stock DeclinesEarnings Revision Downgrade - careplusvn.com
MESO Q1 2026 Earnings: EPS Misses Estimates, Stock DeclinesSlow Growth Warning - dars.gov.et
MESO Q1 2026 Earnings: EPS Misses Estimates, Stock DeclinesProfit Announcement - dars.gov.et
Mesoblast Shares Decline Nearly 5% as Key Support Levels TestedComposite Profile - dars.gov.et
Mesoblast Shares Decline Nearly 5% as Key Support Levels TestedFactor ETF Flow - careplusvn.com
Mesoblast Limited (ASX:MSB) Heats Up Again as Biotech Investors Watch Its Next Move - Kalkine
Mesoblast (ASX: MSB) Slips as Investors Monitor Ryoncil Growth and Product Pipeline - Kalkine
ETFs Investing in Mesoblast Limited Sponsored ADR Stocks - TradingView
Mesoblast Limited (MESO) is a Great Momentum Stock: Should You Buy? - Yahoo Finance
What Triggered Today's Move in the Mesoblast (ASX:MSB) Share Price? - Kalkine
Mesoblast (ASX:MSB) Shares Give Back Ground After a Sharp Rally - Kalkine
Daily Brief Health Care: First Wave BioPharma , NeuroSpectrum Insights, Mesoblast Ltd, Know Labs , Zoetis Inc, CTT Pharmaceutical Holdings, Oncolytics Biotech, ATAI Life Sciences NV and more - Smartkarma
Daily Brief Australia: Genesis Minerals, Perpetual Ltd, Mesoblast Ltd, BHP Group Ltd, Pacific Niugini, D3 Energy, Noble Helium and more - Smartkarma
PayPal, Veradermics, Alibaba And Other Big Stocks Moving Higher On Wednesday - Benzinga
Why Is Mesoblast Stock Up Today? - Kalkine
Mesoblast Limited Announces ASX Quotation for 2.25 Million Shares Issued via Employee Share Option Plan - Kalkine Media
Is Mesoblast (ASX:MSB) Trading Within Its 52-Week Price Range? - Kalkine
Mesoblast Issues 2.25 Million Ordinary Shares Under Employee Share Option Plan - Kalkine
Mesoblast Achieves Target of 300 Treated Patients in Pivotal Phase 3 Trial for Chronic Low Back Pain - GlobeNewswire Inc.
Mesoblast reaches 300-patient enrollment in back pain trial - Investing.com
symbol__ Stock Quote Price and Forecast - CNN
SK Hynix Nasdaq debut: $26.5 billion ADR listing sets record - Yahoo Finance
Mesoblast Reports Strong RYONCIL® Revenue, Exceeding Projections - Sharecafe
Ryoncil® Delivers Net Revenue of US$36M for the Fourth Quarter Ended 30 June 2026 - GlobeNewswire Inc.
Degenerative Disc Disease Market Statistics Expected to Experience Major Growth by 2036, According to DelveInsight | Mesoblast, DiscGenics, Biosplice Therapeutics, BIOPHARM GmbH, Yuhan, Histogen - Barchart.com
Mesoblast Ltd Adr (MESO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Mesoblast Ltd Adr 주식 (MESO) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| George Gregory | Director |
Apr 10 '26 |
Buy |
1.48 |
2,324,072 |
3,439,627 |
8,324,072 |
| George Gregory | Director |
Apr 10 '26 |
Buy |
1.48 |
2,324,072 |
3,439,627 |
8,324,072 |
| George Gregory | Director |
Apr 09 '26 |
Buy |
1.44 |
1,586,890 |
2,277,350 |
13,586,890 |
| George Gregory | Director |
Apr 09 '26 |
Buy |
8.59 |
1,981,890 |
17,015,467 |
13,586,890 |
| George Gregory | Director |
Apr 04 '26 |
Buy |
1.42 |
4,000,000 |
5,680,000 |
12,000,000 |
5.53%
자본화:
|
볼륨(24시간):